Target intelligence / Profile preview

Human complement system components (Complement system)

Target
Complement system
Molecular classification
Enzyme, Receptor, Plasma protein, Serine protease
01

Overview

The human complement system is a complex network of more than 30 plasma and cell-surface proteins that play a critical role in the innate immune response [StatPearls, 2023]. It operates through three primary pathways—classical, lectin, and alternative—which converge at the cleavage of C3 and lead to the formation of the membrane attack complex (MAC) for direct pathogen lysis [UniProt, 2024]. Beyond lysis, the system facilitates opsonization, chemotaxis, and the modulation of adaptive immunity [PubMed: PMC7460431]. Dysregulation or overactivation of the complement cascade is implicated in various rare and chronic diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) [Nature Reviews Drug Discovery, 2021]. Therapeutic strategies focus on inhibiting specific components like C3, C5, or various proteases to mitigate tissue damage and systemic inflammation [NIH: NCATS]. However, because the system is vital for host defense, pharmacological inhibition carries a significant risk of infection by encapsulated bacteria, particularly Neisseria meningitidis [FDA Label: Empaveli, 2021].

Other names
Complement cascadeComplement proteinsComplement factors
02

Mechanism of action

Inhibition of specific complement proteins (e.g., C3, C5, Factor B, Factor D, C1s) or receptors (C5aR1) to prevent the formation of the membrane attack complex (MAC), reduce opsonization, or block pro-inflammatory signaling [Nature Reviews Drug Discovery, 2021].

03

Biological functions

Immune responseInflammationOpsonizationCell lysisChemotaxis
04

Disease associations

Paroxysmal nocturnal hemoglobinuria (PNH)Atypical hemolytic uremic syndrome (aHUS)Generalized myasthenia gravis (gMG)Neuromyelitis optica spectrum disorder (NMOSD)Age-related macular degeneration (AMD)C3 glomerulopathy (C3G)Systemic lupus erythematosus (SLE)
05

Safety considerations

Increased susceptibility to encapsulated bacterial infections (especially Neisseria meningitidis)Requirement for meningococcal vaccinationRisk of breakthrough hemolysisInfusion-related reactions
06

Interacting drugs

Eculizumab

8 more in the full profile.

07

Biomarkers

CH50 (Total complement activity)AH50 (Alternative pathway activity)C3 levelsC4 levelsC5a levelssC5b-9 (Soluble membrane attack complex)

Beyond the preview

Go deeper on Human complement system components (Complement system).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human complement system components (Complement system).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call